Meeting
2022 ASCO Annual Meeting
A cell-free RNA-based next-generation sequencing (NGS) assay for the detection of actionable gene fusions in patients with non–small cell lung cancer (NSCLC).
Authors
Yukti Choudhury
Lucence Diagnostics, Singapore, Singapore
Yukti Choudhury , Chae Yin Cher , Jia Min Ho , Claire Chan , Mun Wei Teh , Kao Chin Ngeow , Michelle Pek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3040)
DOI
10.1200/JCO.2022.40.16_suppl.3040
Abstract #
3040
Poster Bd #
32
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pan-tumor analyses of kinase fusions detected in circulating tumor DNA (ctDNA) and concordance with paired tissue.
First Author: Jessica Kim Lee
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC).
First Author: Christine Megerdichian Parseghian
Poster
2018 ASCO Annual Meeting
Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).
First Author: Ben C. Creelan
Poster
2024 ASCO Annual Meeting
Detection of comprehensive oncogenic driver alteration of non-small cell lung cancer from cytology specimens by multi-gene PCR panel.
First Author: Tetsuya Sakai